Human alloreactive CTL clones: loss and reacquisition of specific cytolytic activity can be regulated by "recombinant" interleukin 2.
S L Wee, A C Ochoa, F H Bach
Abstract
S L Wee, A C Ochoa, F H Bach
Abstract
In this communication, we demonstrate that human alloreactive CTL at the clonal level, can undergo reversible processes vis-a-vis lytic function: from a highly lytic phase to a nonlytic quiescent phase and back to a lytic phase. "Reversion" and reacquisition of function can be controlled by removing or adding back a chromatographically purified product of a human interleukin 2 gene (rIL 2) that appears to serve, either directly or indirectly, as a lysis-inducing signal for these CTL.
OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In this communication, we demonstrate that human alloreactive CTL at the clonal level, can undergo reversible processes vis-a-vis lytic function: from a highly lytic phase to a nonlytic quiescent phase and back to a lytic phase. "Reversion" and reacquisition of function can be controlled by removing or adding back a chromatographically purified product of a human interleukin 2 gene (rIL 2) that appears to serve, either directly or indirectly, as a lysis-inducing signal for these CTL.
Key concepts: CTL*, Lytic cycle, Cytolysis, Reversion, Recombinant DNA, Biology, Interleukin 2, Function (biology)